Aarti Drugs Q2 FY23 revenue up 19%; Profit down 5.6%
Around 62% of the revenues came from the domestic market and 38% from the exports market for Q2 FY23 for a standalone business
Around 62% of the revenues came from the domestic market and 38% from the exports market for Q2 FY23 for a standalone business
The new plant will include a wide range of dosage form capabilities for oral solids, liquids, topicals, films, and manufacturing technologies for granulation, film coating, spray drying, tableting
The newest facility has all the core specialties like Obstetrics and Gynaecology, Orthopaedics, Neurology, Cardiology, Paediatrics, General Surgery, and Urology
None of the observations are related to data integrity and Alembic Pharmaceuticals management believes that they are addressable
NABH shall encourage and provide assistance in onboarding their accredited/certified facilities on ABDM’s Health Facility Registry
Roflumilast Tablets had annual sales of US $248 million in the United States according to IQVIA data
Valbenazine Capsules had annual sales of US $781 million in the United States according to IQVIA data
In Q2 FY23, the overall performance of the company continued to be strong despite the ongoing geo-political challenges impacting supply chain and costs
This first joint plan on One Health aims to create a framework to integrate systems and capacity so that we can collectively better prevent, predict, detect, and respond to health threats
Subscribe To Our Newsletter & Stay Updated